Literature DB >> 15165482

Mapping of SOMU1 and M1 epitopes on the apomucin encoded by the 5' end of the MUC5AC gene.

S Nollet1, F Escande, M P Buisine, M E Forgue-Lafitte, P Kirkham, Y Okada, J Bara.   

Abstract

We have developed 11 monoclonal antibodies (MAbs) against human gastric mucin, (1-13M1, 2-11M1, 2-12M1, 9-13M1, 58M1, 19M1, 21M1, 45M1, 463M, 589M, 62M1), which specifically stained by immunohistochemisty both the human gastric surface mucosa and colon adenoma. Among them, five (19M1, 21M1, 463M, 589M, 62M1) immunoreacted with the peptide encoded by the 3' region of the MUC5AC gene (Nollet et al: Int J Cancer 2002;99:336-343). In this study, we identified in the 5' region of this gene the nucleotide fragments encoding peptides immunoreacting with three other anti-M1 MAbs (1-13M1, 2-11M1 and 9-13M1), as well as the SOMU1 MAb (Sotozono et al: J Immunol Methods 1996;192:187-196). 1-13M1 MAb immunoreacts with peptides, including the Cys 2 and Cys 4 domains. The SOMU1 MAb recognized the Cys 5 domain, and the MAbs 2-11M1 and 9-13M1 the globular D1/D2 and D3 domains, respectively. Using serial sections of the mucosae adjacent to colon adenocarcinomas and colon adenomas, we observed that the anti-M1 and anti-SOMU1 MAbs displayed the same immunostaining patterns. The three anti-M1 MAbs (2-12M1, 58M1, and 45M1) did not react with the products of the MUC5AC gene tested until now. The MUC5AC apomucin is now well characterized by MAbs immunoreacting against seven different epitopes belonging to the different main cystein globular domains of this macromolecule. Such antibodies are useful tools for studying the biosynthesis, polymerization, and degradation of mucin.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15165482     DOI: 10.1089/153685904774129694

Source DB:  PubMed          Journal:  Hybrid Hybridomics        ISSN: 1536-8599


  7 in total

1.  Blood group related antigens in ocular cicatricial pemphigoid.

Authors:  C Creuzot-Garcher; T H Xuan; A M Bron; H Robin; P d'Athis; J Bara
Journal:  Br J Ophthalmol       Date:  2004-10       Impact factor: 4.638

2.  Assay of mucins in human tear fluid.

Authors:  Sandra Spurr-Michaud; Pablo Argüeso; Ilene Gipson
Journal:  Exp Eye Res       Date:  2007-02-07       Impact factor: 3.467

Review 3.  Ramifications of secreted mucin MUC5AC in malignant journey: a holistic view.

Authors:  Shiv Ram Krishn; Koelina Ganguly; Sukhwinder Kaur; Surinder K Batra
Journal:  Carcinogenesis       Date:  2018-05-03       Impact factor: 4.944

4.  Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer.

Authors:  Kelly E Henry; Travis M Shaffer; Kyeara N Mack; Janine Ring; Anuja Ogirala; Susanne Klein-Scory; Christina Eilert-Micus; Wolff Schmiegel; Thilo Bracht; Barbara Sitek; Marguerite Clyne; Colm J Reid; Bence Sipos; Jason S Lewis; Holger Kalthoff; Jan Grimm
Journal:  J Nucl Med       Date:  2021-03-12       Impact factor: 10.057

5.  Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic target for pancreatic cancer.

Authors:  Donglin Liu; Chien-Hsing Chang; David V Gold; David M Goldenberg
Journal:  Oncotarget       Date:  2015-02-28

6.  Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin.

Authors:  David V Gold; Guy Newsome; Donglin Liu; David M Goldenberg
Journal:  Mol Cancer       Date:  2013-11-20       Impact factor: 27.401

7.  Pyocyanin-induced mucin production is associated with redox modification of FOXA2.

Authors:  Yonghua Hao; Zhizhou Kuang; Ying Xu; Brent E Walling; Gee W Lau
Journal:  Respir Res       Date:  2013-08-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.